{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T16:42:24Z","timestamp":1780418544906,"version":"3.54.1"},"reference-count":75,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T00:00:00Z","timestamp":1724630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Surg."],"abstract":"<jats:p>The prevalence and severity of overactive bladder increase with age, and mirabegron is an approved treatment for this condition. This meta-analysis systematically evaluated the efficacy and safety of mirabegron compared with placebo for overactive bladder treatment. We searched PubMed and the Cochrane Library (30 October 2023) for relevant articles (source: MEDLINE, EMBASE, ClinicalTrials.gov, ICTRP, CINAHL). We included randomized controlled trials involving adults with overactive bladder syndrome that compared mirabegron with placebo treatment. Data were analyzed according to the Cochrane Handbook for Systematic Reviews of Interventions [Review Manager (computer program) Version 5.4]. Nine parallel-group trials (10 articles) were included. The evaluation included a total of 8,527 adults, including 6,445 women and 2,082 men, of whom 5,726 were White, 2,462 were Asian, and 161 were Black. The mean age of the participants ranged from 53.4 to 60.3 years. This evaluation involved three specifications of mirabegron: 25\u2005mg, 50\u2005mg, and 100\u2005mg. In all trials, patients were enrolled in a 12-week double-blind treatment period, and the dose was once daily. The review of trials found that on average, people taking mirabegron had about 13\u2005ml more volume voided per micturition, five fewer micturitions, and four fewer incontinence episodes every week, with moderate improvements in quality of life. About one in five people taking the drug reported TRAEs. Mirabegron treatment is well tolerated, with the risk of adverse events similar to that of a placebo. For best results, a dose of 50\u2005mg once daily is recommended for long-term use. It is unclear whether any benefits are sustained after treatment discontinuation.<\/jats:p><jats:p><jats:bold>Systematic Review Registration<\/jats:bold>: <jats:uri>https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:uri>, PROSPERO (CRD42023430737).<\/jats:p>","DOI":"10.3389\/fsurg.2024.1372175","type":"journal-article","created":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T05:05:57Z","timestamp":1724648757000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Mirabegron 50\u2005mg once daily, long-term treatment maximizes benefit in middle-aged and older people with overactive bladder syndrome: a systematic review and meta-analysis of nine phase II\/III, randomized, double-blind, parallel-design, placebo-controlled, multicenter, and multinational trials"],"prefix":"10.3389","volume":"11","author":[{"given":"Xiangxiang","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinhui","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jilei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juntao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenli","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhitao","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,8,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/nau.10052","article-title":"The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the International Continence Society","volume":"21","author":"Abrams","year":"2002","journal-title":"Neurourol Urodyn"},{"key":"B2","doi-asserted-by":"publisher","first-page":"CD005429","DOI":"10.1002\/14651858.CD005429.pub2","article-title":"Which anticholinergic drug for overactive bladder symptoms in adults","volume":"1","author":"Madhuvrata","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1111\/j.1464-410X.2010.09993.x","article-title":"Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction","volume":"108","author":"Irwin","year":"2011","journal-title":"BJU Int"},{"key":"B4","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1046\/j.1464-410x.2001.02228.x","article-title":"How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study","volume":"87","author":"Milsom","year":"2001","journal-title":"BJU Int"},{"key":"B5","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s00345-002-0301-4","article-title":"Prevalence and burden of overactive bladder in the United States","volume":"20","author":"Stewart","year":"2003","journal-title":"World J Urol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.mayocp.2019.11.024","article-title":"Evaluation and treatment of overactive bladder in women","volume":"95","author":"Raju","year":"2020","journal-title":"Mayo Clin Proc"},{"key":"B7","first-page":"682","article-title":"Epidemiology of over-active bladder (OAB) syndrome","volume":"155","author":"Eshkoli","year":"2016","journal-title":"Harefuah"},{"key":"B8","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1002\/nau.22429","article-title":"The prevalence and risk factors of OAB in middle-aged and old people in China","volume":"33","author":"Wen","year":"2014","journal-title":"Neurourol Urodyn"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e27469","DOI":"10.1097\/MD.0000000000027469","article-title":"Monotherapy with mirabegron had a better tolerance than the anticholinergic agents on overactive bladder: a systematic review and meta-analysis","volume":"100","author":"Yi","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"B10","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/j.eururo.2019.02.038","article-title":"A comprehensive review of overactive bladder pathophysiology: on the way to tailored treatment","volume":"75","author":"Peyronnet","year":"2019","journal-title":"Eur Urol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.eururo.2018.03.020","article-title":"Efficacy and tolerability of mirabegron compared with antimuscarinic monotherapy or combination therapies for overactive bladder: a systematic review and network meta-analysis","volume":"74","author":"Kelleher","year":"2018","journal-title":"Eur Urol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"5452","DOI":"10.1007\/s12325-021-01902-8","article-title":"Efficacy of vibegron and mirabegron for overactive bladder: a systematic literature review and indirect treatment comparison","volume":"38","author":"Kennelly","year":"2021","journal-title":"Adv Ther"},{"key":"B13","doi-asserted-by":"publisher","first-page":"575","DOI":"10.2147\/CIA.S174402","article-title":"Mirabegron in the treatment of overactive bladder: safety and efficacy in the very elderly patient","volume":"15","author":"Makhani","year":"2020","journal-title":"Clin Interv Aging"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1016\/j.euf.2018.03.011","article-title":"Oral pharmacologic management of overactive bladder syndrome: where do we stand?","volume":"5","author":"Marcelissen","year":"2019","journal-title":"Eur Urol Focus"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.2147\/CIA.S252852","article-title":"Cognitive effects of anticholinergic load in women with overactive bladder","volume":"15","author":"Araklitis","year":"2020","journal-title":"Clin Interv Aging"},{"key":"B16","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.ejogrb.2020.05.018","article-title":"Mirabegron in female patients with overactive bladder syndrome: what\u2019s new? A systematic review and meta-analysis","volume":"251","author":"Athanasiou","year":"2020","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1177\/2042098616659412","article-title":"Mirabegron in overactive bladder patients: efficacy review and update on drug safety","volume":"7","author":"Warren","year":"2016","journal-title":"Ther Adv Drug Saf"},{"key":"B18","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1111\/bph.13367","article-title":"Mirabegron relaxes urethral smooth muscle by a dual mechanism involving \u03b23-adrenoceptor activation and \u03b11-adrenoceptor blockade","volume":"173","author":"Alexandre","year":"2016","journal-title":"Br J Pharmacol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/iju.13498","article-title":"Systematic review and meta-analysis on the efficacy and tolerability of mirabegron for the treatment of storage lower urinary tract symptoms\/overactive bladder: comparison with placebo and tolterodine","volume":"25","author":"Sebastianelli","year":"2018","journal-title":"Int J Urol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.eururo.2014.02.012","article-title":"Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (symphony)","volume":"67","author":"Abrams","year":"2015","journal-title":"Eur Urol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1007\/s00192-013-2042-x","article-title":"A phase II dose-ranging study of mirabegron in patients with overactive bladder","volume":"24","author":"Chapple","year":"2013","journal-title":"Int Urogynecol J"},{"key":"B22","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.urology.2013.02.077","article-title":"A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the \u03b2\u2083 adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder","volume":"82","author":"Herschorn","year":"2013","journal-title":"Urology"},{"key":"B23","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1111\/bju.13882","article-title":"Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study)","volume":"120","author":"Herschorn","year":"2017","journal-title":"BJU Int"},{"key":"B24","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1002\/nau.23315","article-title":"Patient-reported outcomes from SYNERGY, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with monotherapy and placebo in OAB patients","volume":"37","author":"Robinson","year":"2018","journal-title":"Neurourol Urodyn"},{"key":"B25","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.eururo.2012.10.016","article-title":"Efficacy and tolerability of mirabegron, a \u03b2(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial","volume":"63","author":"Khullar","year":"2013","journal-title":"Eur Urol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1002\/nau.22645","article-title":"Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a \u03b23-adrenoceptor agonist, in patients with overactive bladder in Asia","volume":"34","author":"Kuo","year":"2015","journal-title":"Neurourol Urodyn"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.juro.2012.10.017","article-title":"Results of a randomized phase III trial of mirabegron in patients with overactive bladder","volume":"189","author":"Nitti","year":"2013","journal-title":"J Urol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1111\/bju.12649","article-title":"Phase III, randomised, double-blind, placebo-controlled study of the \u03b23-adrenoceptor agonist mirabegron, 50mg once daily, in Japanese patients with overactive bladder","volume":"113","author":"Yamaguchi","year":"2014","journal-title":"BJU Int"},{"key":"B29","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/luts.12053","article-title":"Efficacy and safety of the selective \u03b23-adrenoceptor agonist mirabegron in Japanese patients with overactive bladder: a randomized, double-blind, placebo-controlled, dose-finding study","volume":"7","author":"Yamaguchi","year":"2015","journal-title":"Low Urin Tract Symptoms"},{"key":"B30","doi-asserted-by":"publisher","first-page":"CD003781","DOI":"10.1002\/14651858.CD003781.pub2","article-title":"Anticholinergic drugs versus placebo for overactive bladder syndrome in adults","volume":"2006","author":"Nabi","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"B31","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1007\/s00345-016-1908-1","article-title":"Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, phase II study (SYMPHONY)","volume":"35","author":"Abrams","year":"2017","journal-title":"World J Urol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.eururo.2012.10.048","article-title":"Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a \u03b2(3)-adrenoceptor agonist, in overactive bladder","volume":"63","author":"Chapple","year":"2013","journal-title":"Eur Urol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1002\/nau.22373","article-title":"A proof-of-concept study: mirabegron, a new therapy for overactive bladder","volume":"32","author":"Chapple","year":"2013","journal-title":"Neurourol Urodyn"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1007\/s00345-014-1244-2","article-title":"Onset of action of the \u03b23-adrenoceptor agonist, mirabegron, in phase II and III clinical trials in patients with overactive bladder","volume":"32","author":"Chapple","year":"2014","journal-title":"World J Urol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1007\/s11136-014-0904-4","article-title":"The effect of mirabegron on patient-related outcomes in patients with overactive bladder: the results of post hoc correlation and responder analyses using pooled data from three randomized phase III trials","volume":"24","author":"Castro-Diaz","year":"2015","journal-title":"Qual Life Res"},{"key":"B36","doi-asserted-by":"publisher","first-page":"O53","DOI":"10.1111\/luts.12215","article-title":"Therapeutic efficacy of low-dose (25mg) mirabegron therapy for patients with mild to moderate overactive bladder symptoms due to central nervous system diseases","volume":"11","author":"Chen","year":"2019","journal-title":"Low Urin Tract Symptoms"},{"key":"B37","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.eururo.2019.09.024","article-title":"Safety and efficacy of mirabegron: analysis of a large integrated clinical trial database of patients with overactive bladder receiving mirabegron, antimuscarinics, or placebo","volume":"77","author":"Chapple","year":"2020","journal-title":"Eur Urol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1002\/nau.24552","article-title":"Mirabegron for treatment of overactive bladder symptoms in patients with Parkinson\u2019s disease: a double-blind, randomized placebo-controlled trial (Parkinson\u2019s disease overactive bladder mirabegron, PaDoMi study)","volume":"40","author":"Cho","year":"2021","journal-title":"Neurourol Urodyn"},{"key":"B39","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/luts.12481","article-title":"Mirabegron is better tolerated than solifenacin in Sjogren\u2019s syndrome patients with overactive bladder symptoms-A randomized controlled trial","volume":"15","author":"Chen","year":"2023","journal-title":"Low Urin Tract Symptoms"},{"key":"B40","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.eururo.2016.02.030","article-title":"Efficacy and safety of mirabegron add-on therapy to solifenacin in incontinent overactive bladder patients with an inadequate response to initial 4-week solifenacin monotherapy: a randomised double-blind multicentre phase 3B study (BESIDE)","volume":"70","author":"Drake","year":"2016","journal-title":"Eur Urol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"e12944","DOI":"10.1111\/ijcp.12944","article-title":"Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add-on mirabegron therapy to solifenacin (BESIDE)","volume":"71","author":"Drake","year":"2017","journal-title":"Int J Clin Pract"},{"key":"B42","doi-asserted-by":"publisher","first-page":"838","DOI":"10.5414\/CP201782","article-title":"Single dose pharmacokinetics and absolute bioavailability of mirabegron, a \u03b2\u2083-adrenoceptor agonist for treatment of overactive bladder","volume":"50","author":"Eltink","year":"2012","journal-title":"Int J Clin Pharmacol Ther"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1016\/j.juro.2016.03.044","article-title":"Re: a randomized, controlled trial of effectiveness and safety of management of OAB symptoms in elderly men and women with standard-dosed combination of solifenacin and mirabegron","volume":"195","author":"Griebling","year":"2016","journal-title":"J Urol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.euf.2017.08.008","article-title":"Treating overactive bladder in older patients with a combination of mirabegron and solifenacin: a prespecified analysis from the BESIDE study","volume":"3","author":"Gibson","year":"2017","journal-title":"Eur Urol Focus"},{"key":"B45","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.eururo.2018.05.005","article-title":"Long-term safety and efficacy of mirabegron and solifenacin in combination compared with monotherapy in patients with overactive bladder: a randomised, multicentre phase 3 study (SYNERGY II)","volume":"74","author":"Gratzke","year":"2018","journal-title":"Eur Urol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s12877-020-1474-7","article-title":"Effect of mirabegron on cognitive function in elderly patients with overactive bladder: MoCA results from a phase 4 randomized, placebo-controlled study (PILLAR)","volume":"20","author":"Griebling","year":"2020","journal-title":"BMC Geriatr"},{"key":"B47","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/luts.12167","article-title":"Comparisons of the clinical outcomes and urodynamic effects of mirabegron versus tolterodine treatment for female overactive bladder syndrome: a subgroup analysis of a controlled, randomised, prospective study","volume":"10","author":"Hsiao","year":"2018","journal-title":"Low Urin Tract Symptoms"},{"key":"B48","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12955-018-0892-0","article-title":"Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER)","volume":"16","author":"Herschorn","year":"2018","journal-title":"Health Qual Life Outcomes"},{"key":"B49","doi-asserted-by":"publisher","first-page":"14219","DOI":"10.1038\/s41598-022-18391-6","article-title":"Impact of mirabegron versus solifenacin on autonomic function and arterial stiffness in female overactive bladder syndrome: a randomized controlled trial","volume":"12","author":"Hsiao","year":"2022","journal-title":"Sci Rep"},{"key":"B50","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1186\/s13063-023-07279-z","article-title":"Treating incontinence for underlying mental and physical health (TRIUMPH): a study protocol for a multicenter, double-blinded, randomized, 3-arm trial to evaluate the multisystem effects of pharmacologic treatment strategies for urgency-predominant urinary incontinence in ambulatory older women","volume":"24","author":"Huang","year":"2023","journal-title":"Trials"},{"key":"B51","doi-asserted-by":"publisher","first-page":"387","DOI":"10.18926\/AMO\/57368","article-title":"Comparison of two different drugs for overactive bladder, solifenacin and mirabegron: a prospective randomized crossover study","volume":"73","author":"Inoue","year":"2019","journal-title":"Acta Med Okayama"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1007\/s11255-020-02412-2","article-title":"Italian real-life clinical setting: the persistence and adherence with mirabegron in women with overactive bladder","volume":"52","author":"Illiano","year":"2020","journal-title":"Int Urol Nephrol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"825","DOI":"10.3390\/medicina58060825","article-title":"Impact of mirabegron administration on the blood pressure and pulse rate in patients with overactive bladder","volume":"58","author":"Ito","year":"2022","journal-title":"Medicina (Kaunas)"},{"key":"B54","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/1471-2490-13-45","article-title":"Efficacy of mirabegron in patients with and without prior antimuscarinic therapy for overactive bladder: a post hoc analysis of a randomized European-Australian phase 3 trial","volume":"13","author":"Khullar","year":"2013","journal-title":"BMC Urol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.archger.2015.06.006","article-title":"A randomized, controlled trial of effectiveness and safety of management of OAB symptoms in elderly men and women with standard-dosed combination of solifenacin and mirabegron","volume":"61","author":"Kosilov","year":"2015","journal-title":"Arch Gerontol Geriatr"},{"key":"B56","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1002\/nau.23566","article-title":"Efficacy and safety of mirabegron for the treatment of neurogenic detrusor overactivity-prospective, randomized, double-blind, placebo-controlled study","volume":"37","author":"Krhut","year":"2018","journal-title":"Neurourol Urodyn"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1007\/s11255-020-02774-7","article-title":"Cardiovascular safety of mirabegron in individuals treated for spinal cord injury- or multiple sclerosis-induced neurogenic detrusor overactivity","volume":"53","author":"Krhut","year":"2021","journal-title":"Int Urol Nephrol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.urology.2023.02.003","article-title":"Comparison of mirabegron and vibegron in women with treatment-naive overactive bladder: a randomized controlled study","volume":"175","author":"Kinjo","year":"2023","journal-title":"Urology"},{"key":"B59","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.jfma.2018.08.014","article-title":"Mirabegron escalation to 50mg further improves daily urgency and urgency urinary incontinence in Asian patients with overactive bladder","volume":"118","author":"Liao","year":"2019","journal-title":"J Formos Med Assoc"},{"key":"B60","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/clpt.2012.181","article-title":"Proarrhythmic safety of repeat doses of mirabegron in healthy subjects: a randomized, double-blind, placebo-, and active-controlled thorough QT study","volume":"92","author":"Malik","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"B61","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1002\/nau.23919","article-title":"Long-term treatment of older patients with overactive bladder using a combination of mirabegron and solifenacin: a prespecified analysis from the randomized, phase III SYNERGY II study","volume":"38","author":"Mueller","year":"2019","journal-title":"Neurourol Urodyn"},{"key":"B62","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1080\/21681805.2021.1990994","article-title":"The safety and effectiveness of mirabegron in Parkinson\u2019s disease patients with overactive bladder: a randomized controlled trial","volume":"56","author":"Moussa","year":"2022","journal-title":"Scand J Urol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.urology.2021.12.018","article-title":"Mirabegron reduces urinary frequency and improves overactive bladder symptoms at 3 months after 125I-brachytherapy for prostate cancer: an open-labeled, randomized, non-placebo-controlled study","volume":"161","author":"Nakai","year":"2022","journal-title":"Urology"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1111\/iju.13231","article-title":"Comparison of mirabegron and imidafenacin for efficacy and safety in Japanese female patients with overactive bladder: a randomized controlled trial (COMFORT study)","volume":"23","author":"Otsuka","year":"2016","journal-title":"Int J Urol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1590\/S1677-5538.IBJU.2018.0518","article-title":"Efficacy and tolerability of mirabegron in female patients with overactive bladder symptoms after surgical treatment for stress urinary incontinence","volume":"45","author":"\u00d6zkidik","year":"2019","journal-title":"Int Braz J Urol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1007\/s00192-016-3219-x","article-title":"Is mirabegron equally as effective when used as first- or second-line therapy in women with overactive bladder?","volume":"28","author":"Serati","year":"2017","journal-title":"Int Urogynecol J"},{"key":"B67","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s00192-017-3377-5","article-title":"A prospective, double-blind, randomized, two-period crossover, multicenter study to evaluate tolerability and patient preference between mirabegron and tolterodine in patients with overactive bladder (PREFER study)","volume":"29","author":"Staskin","year":"2018","journal-title":"Int Urogynecol J"},{"key":"B68","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1111\/iju.14608","article-title":"Effect of oxybutynin patch versus mirabegron on nocturia-related quality of life in female overactive bladder patients: a multicenter randomized trial","volume":"28","author":"Suzuki","year":"2021","journal-title":"Int J Urol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1002\/nau.23050","article-title":"Clinical efficacy and safety of mirabegron and imidafenacin in women with overactive bladder: a randomized crossover study (the MICRO study)","volume":"36","author":"Torimoto","year":"2017","journal-title":"Neurourol Urodyn"},{"key":"B70","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1159\/000445808","article-title":"Comparison of therapeutic efficacy and urodynamic findings of solifenacin succinate versus mirabegron in women with overactive bladder syndrome: results of a randomized controlled study","volume":"97","author":"Vecchioli Scaldazza","year":"2016","journal-title":"Urol Int"},{"key":"B71","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.juro.2018.05.139","article-title":"Re: efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study)","volume":"200","author":"Wein","year":"2018","journal-title":"J Urol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1097\/MBP.0000000000000320","article-title":"A strategy utilizing ambulatory monitoring and home and clinic blood pressure measurements to optimize the safety evaluation of noncardiovascular drugs with potential for hemodynamic effects: a report from the SYNERGY trial","volume":"23","author":"Weber","year":"2018","journal-title":"Blood Press Monit"},{"key":"B73","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.1002\/nau.23774","article-title":"A pilot randomized-controlled trial of the urodynamic efficacy of mirabegron for patients with neurogenic lower urinary tract dysfunction","volume":"37","author":"Welk","year":"2018","journal-title":"Neurourol Urodyn"},{"key":"B74","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.eururo.2019.10.002","article-title":"Efficacy, safety, and tolerability of mirabegron in patients aged \u226565yr with overactive bladder wet: a phase IV, double-blind, randomised, placebo-controlled study (PILLAR)","volume":"77","author":"Wagg","year":"2020","journal-title":"Eur Urol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/luts.12384","article-title":"Adding mirabegron after intravesical onabotulinumtoxinA injection improves therapeutic effects in patients with refractory overactive bladder","volume":"13","author":"Wang","year":"2021","journal-title":"Low Urin Tract Symptoms"}],"container-title":["Frontiers in Surgery"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fsurg.2024.1372175\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T05:06:04Z","timestamp":1724648764000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fsurg.2024.1372175\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,26]]},"references-count":75,"alternative-id":["10.3389\/fsurg.2024.1372175"],"URL":"https:\/\/doi.org\/10.3389\/fsurg.2024.1372175","relation":{},"ISSN":["2296-875X"],"issn-type":[{"value":"2296-875X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,26]]},"article-number":"1372175"}}